EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome

Roberto Vendramin, Hongchang Fu, Shanila Fernandez Patel, Yue Zhao, Danwen Qian, Lorena Ligammari, Osnat Bartok, Polina Greenberg, Ronen Levy, Andrea Castro, Krupa Thakkar, Jun Murai und 26 weitere

Immunity · 2026-05 · 59 (5) · 1398-1421.e20

DOI: 10.1016/j.immuni.2026.02.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, 2026-05. Verfasst von Roberto Vendramin und 37 weiteren Autor:innen. Beteiligte Einrichtung: The Tumor Immunogenomics and Immunosurveillance Lab, University College London Cancer Institute, London, UK; Cancer Evolution and Genome Instability …. Hauptthemen laut MEDLINE: Nonsense Mediated mRNA Decay, Antigens, Neoplasm, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, National Institute for Health and Care Research, CRUK Lung Cancer Centre of Excellence.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA mutations are a well-characterized source of neoepitopes in immunotherapy. Here, we examined the contribution of dysregulated RNA processing to neoantigen production. Leveraging multi-omics and checkpoint inhibitor (CPI) response data from >1,000 patients, we identified reduced activity of the nonsense-mediated mRNA decay (NMD) pathway kinase SMG1 as a predictor of improved CPI response. NMD inhibition through SMG1 targeting stabilized transcripts containing premature termination codons, most of which were of non-mutational origin. This reshaped the major histocompatibility complex class I (MHC class I)-bound immunopeptidome and increased neoantigen abundance to levels comparable to high mutation burden tumors. Functionally, NMD inhibition drove antigen-dependent T cell-mediated tumor cell killing in vitro, promoted activation of tissue-resident T cells in patient-derived models ex vivo, and improved CPI efficacy in vivo. Our findings establish NMD inhibition as a strategy to harness a previously inaccessible source of canonical and non-canonical neoantigens, with the potential to increase tumor immunogenicity across cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nonsense Mediated mRNA DecayAntigens, NeoplasmNeoplasmsHumansAnimalsMiceCell Line, TumorHistocompatibility Antigens Class IPhosphatidylinositol 3-KinasesImmune Checkpoint InhibitorsT-LymphocytesImmunotherapyProtein Serine-Threonine Kinases

Stichwörter der Autor:innen

SMG1cancer immunopeptidomecancer immunotherapycryptic peptidesnon-canonical neoantigensnonsense-mediated mRNA decaypatient-derived fragmentstumor immunogenicity

Substanzen

Antigens, NeoplasmSMG1 protein, humanHistocompatibility Antigens Class IPhosphatidylinositol 3-KinasesImmune Checkpoint InhibitorsProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • The Tumor Immunogenomics and Immunosurveillance Lab, University College London Cancer Institute, London, UK; Cancer Evolution and Genome Instability Lab, The Francis Crick Institute, London, UK; CRUK Lung Cancer Centre…
  • The Tumor Immunogenomics and Immunosurveillance Lab, University College London Cancer Institute, London, UK; CRUK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Pre-Cancer Immu…
  • The Tumor Immunogenomics and Immunosurveillance Lab, University College London Cancer Institute, London, UK; CRUK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Organelle Dynam…
  • The Tumor Immunogenomics and Immunosurveillance Lab, University College London Cancer Institute, London, UK; CRUK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Department of T…
  • The Tumor Immunogenomics and Immunosurveillance Lab, University College London Cancer Institute, London, UK; CRUK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.

Förderung

  • Wellcome Trust
  • National Institute for Health and Care Research
  • CRUK Lung Cancer Centre of Excellence
  • EU Framework Programme for Research and Innovation Marie Skłodowska-Curie Actions
  • Breast Cancer Research Foundation
  • Royal Society
  • The Mark Foundation for Cancer Research
  • European Association For Cancer Research

Zitieren

APA

Vendramin, R., Fu, H., Fernandez Patel, S., Zhao, Y., Qian, D., Ligammari, L., Bartok, O., Greenberg, P., Levy, R., Castro, A., Thakkar, K., Murai, J., Lu, W. T., Sng, C. C. T., Weller, C., Beattie, G., Bhamra, A., Farriol-Duran, R., Karagianni, D., …, & Litchfield, K. (2026). Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome. Immunity, 59(5), 1398-1421.e20. https://doi.org/10.1016/j.immuni.2026.02.005

Vancouver

Vendramin R, Fu H, Fernandez Patel S, Zhao Y, Qian D, Ligammari L, et al. Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome. Immunity. 2026;59(5):1398-1421.e20. doi:10.1016/j.immuni.2026.02.005

BibTeX
@article{Vendramin2026,
  author = {Vendramin, Roberto and Fu, Hongchang and Fernandez Patel, Shanila and Zhao, Yue and Qian, Danwen and Ligammari, Lorena and Bartok, Osnat and Greenberg, Polina and Levy, Ronen and Castro, Andrea and Thakkar, Krupa and Murai, Jun and Lu, Wei-Ting and Sng, Christopher C T and Weller, Chen and Beattie, Gordon and Bhamra, Amandeep and Farriol-Duran, Roc and Karagianni, Despoina and Augustine, Marcellus and Dijkstra, Krijn K and Pinder, Christopher L and Simpson, Benjamin S and Cheung, Gordon Weng-Kit and TRACERx Consortium, TRACERx Consortium and Galvez-Cancino, Felipe and Vlckova, Petra and Surinova, Silvia and Rodriguez-Justo, Manuel and Shah, Mansi and McGranahan, Nicholas and Carlton, Jeremy G and Grönroos, Eva and Reading, James L and Samuels, Yardena and Swanton, Charles and Quezada, Sergio A and Litchfield, Kevin},
  title = {Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome},
  journal = {Immunity},
  year = {2026},
  volume = {59},
  number = {5},
  pages = {1398--1421.e20},
  doi = {10.1016/j.immuni.2026.02.005}
}
Kostenlos starten →